Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $298.3 million.

  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization rose 294596.14% to $298.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.3 million, marking a year-over-year increase of 294596.14%. This contributed to the annual value of $271.6 million for FY2024, which is 95523.95% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $298.3 million for Q3 2025, which was up 294596.14% from $290.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $298.3 million during Q3 2025, with a 5-year trough of $2.5 million in Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $65.8 million, with its median value being $9.7 million (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization surged by 180.89% in 2024 and then soared by 294596.14% in 2025.
  • Amphastar Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $10.2 million in 2021, then grew by 23.2% to $12.6 million in 2022, then surged by 104.31% to $25.7 million in 2023, then soared by 955.24% to $271.6 million in 2024, then grew by 9.83% to $298.3 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $298.3 million for Q3 2025, versus $290.5 million for Q2 2025 and $280.0 million for Q1 2025.